MedTrace Logo

A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma

NCT07393542 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 453

Last updated 2026-08-14

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy of SHR-A2102 with adebrelimab versus gemcitabine in combination with cisplatin/carboplatin in previously untreated locally advanced or metastatic urothelial carcinoma.

Conditions

  • Locally Advanced or Metastatic Urothelial Carcinoma

Interventions

DRUG

SHR-A2102 and Adebrelimab

SHR-A2102 and Adebrelimab injection

DRUG

Gemcitabine and cisplatin / carboplatin

Gemcitabine injection and cisplatin injection / carboplatin injection

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-12
Primary Completion
2028-01-31
Completion
2030-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07393542 on ClinicalTrials.gov